The fight against Ebola continues as global health organizations work to fast-track a vaccine specifically for the Bundibugyo species. This lesser-known species is causing problems in the Democratic Republic of Congo (DRC) and Uganda. The approved Ebola vaccine, Ervebo, is not designed to tackle this variant.
Two major non-profits have pledged substantial funds to jump-start the project. The Coalition for Epidemic Preparedness Innovation (CEPI) is earmarking $62 million. Gavi, a global vaccine alliance, is contributing an additional $40 million. These funds will support research and development efforts by several institutions.
Research and Development Efforts
Research institutions are now involved in advancing vaccine candidates with different strengths. IAVI is utilizing a vesicular stomatitis virus (VSV) in its approach. Previous studies demonstrated its effectiveness in animal trials. However, scaling up production for larger trials will take several months.
The University of Oxford is building a vaccine similar to their COVID-19 vaccine, preparing doses jointly with the Serum Institute of India. They estimate availability in one to two months.
Moderna is working on an mRNA-based vaccine, promising rapid development. However, the strategy regarding dosing is yet unclear.
The Challenge of Clinical Trials
Conducting trials in DRC and Uganda poses significant challenges. Factors such as ongoing conflict and misinformation about vaccines complicate efforts. Various rumors harm trust among communities, making recruitment and participation difficult.
Efforts are underway to engage local organizations and communities in facilitating a smoother trial process. WHO’s involvement aims to enhance cooperation, ensuring trials evaluate vaccine safety and efficacy rigorously.
Leave a Reply